The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy.
Mehigan
B J
BJ
Kerin
M J
MJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000628:therapy*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism*; D015854:Up-Regulation
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases